News

Formerly a division of Richmond, VA-based Alliance Engineering, Alliance Biosciences was the leading biosafety and biosecurity consulting firm in the United States. With this addition, WCG’s biosafety division

Zydelig has been approved by The U.S. Food and Drug Administration (FDA) for the treatment of three different B-cell blood cancers: 1. In combination with rituximab for patients

KX2-391 is a synthetic, orally active and highly selective inhibitor of Src tyrosine kinase signaling and tubulin polymerization. KX2-391 promotes the induction of p53, G2/M arrest of proliferating

The filing of the application will follow the Article 58 procedure, which enables the EMA to evaluate the quality, safety and efficacy of a candidate vaccine, or medicine,

Malignant hyperthermia is an inherited and potentially fatal disorder triggered by certain anesthesia agents in genetically susceptible individuals. The FDA had granted orphan drug designated to Ryanodex in

The new product, which will be launched after Health Canada approval, uses a patented delivery system that provides technical advantages over existing alternatives and will be used in

NPC is a rare disease seen mostly of children who are afflicted with Alzheimer-like symptoms. According to the company, the licence also covers other diseases and disorders relying

According to the company, Plegridy can be taken by injection once every two weeks and administered under the skin with a prefilled auto-injector. Biogen Idec chief executive officer

The company also announced that it has received an additional commitment from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), to